Loading…
← CockpitCompetitor Analysis › 688114.SS MGI Tech Co., Ltd. Class AOpen in the cockpit ↗

MGI Tech Co., Ltd. Class A688114.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese maker of DNA sequencing instruments and reagents, spun off from BGI Genomics, competing with Illumina.

≈ China's Illumina (DNA sequencing instruments)Momentum neutral 44
Mkt cap
$3.06B
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$65.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-5.9 pp
WACC 7.7%
Hurdle
+44 pp
Req g minus delivered
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥50.58
1D-4.7%
1W-14.5%
1M-20.4%
3M-28.0%
6M-3.5%
YTD-16.8%
1Y-26.0%
ATR %7.8%
52w lowhigh39.0% off high

What MGI Tech does

Chinese maker of DNA sequencing instruments and reagents, spun off from BGI Genomics, competing with Illumina.

Sells sequencers once, then earns repeatedly on the reagents (chemicals and consumables) each run uses, so the installed base of machines is what generates ongoing revenue. BGI, the genomics group it was spun out of, is both a major customer and a related party.

In one line: China's Illumina (DNA sequencing instruments).

Products and services

  • Sequencing instruments
  • Sequencing reagents/consumables
  • Lab automation systems

Customers

  • Genomics/research labs
  • Hospitals
  • Sequencing service providers (incl. BGI)

Where it sits in the supply chain

  • Health Care
  • Life-science tools
  • Genomics/DNA sequencing instruments

What could go right

  • Genomics/precision-medicine adoption growth

What could go wrong

  • Illumina patent-litigation risk
  • Customer concentration in BGI-affiliated labs

Moat: narrow (IP / patents, switching costs, installed base). Instrument-reagent lock-in and patented sequencing chemistry favor the installed-base leader.

Headquarters: Shenzhen, Guangdong, China · Employees: 2,195

Named competitors

MGI Tech at a glance

Size MGI Tech (688114.SS) is a China Health Care company (Medical Specialties) with a market value of $3.06B, the 794th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥50.58 on 18 Nov 2026.

Performance Over six months the shares fell 3.5%, against +6.8% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 1.6% over the last twelve months (peer median +7.2%); the operating margin is -7.4% (peer median 10.2%).

Valuation It trades at 5.9× enterprise value to sales against a peer median of 4.1× (4th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +44 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.9 points below its cost of capital (7.7% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026Peer median 109688114.SS 96
Six months, rebased to 100: MGI Tech against the median of its 20 peers (local-currency closes).

MGI Tech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.06BCN¥2.77BCN¥3.00BCN¥2.90BCN¥4.21B
Revenue growth—-8%+3%-31%—
Gross profitCN¥1.82BCN¥1.12BCN¥1.33BCN¥1.37BCN¥2.07B
EBITDAn/aCN¥41.8M-CN¥200M-CN¥497MCN¥402M
Net income-CN¥290M-CN¥222M-CN¥601M-CN¥607MCN¥2.03B
Free cash flowCN¥535MCN¥48.3M-CN¥1.16B-CN¥1.63BCN¥499M
Capital expenditureCN¥438MCN¥194MCN¥385MCN¥758MCN¥938M
Total debtCN¥1.44BCN¥1.10BCN¥855MCN¥466MCN¥206M

Quarterly statements and history in the cockpit →

MGI Tech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%AFXIRTC300003603301688301ATRCTMDX603658COTNPLSEAXGNCELCAMBU-B4203OBCKTECN6030141SXPEBOMOVE688114.SS6-month return →1-month return →
Up and to the right = strong over both horizons. MGI Tech is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×1,000×2,000×AFXIRTCPLSE688114.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. MGI Tech is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%AFXIRTC300003603301ATRCTMDX603658OBCKTECN1SXP688114.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. MGI Tech is the large dot.

MGI Tech competitors and peer comparison

Head to head with its named competitors (688114.SS vs ILMN vs TMO vs PACB)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
MGI Tech 688114.SS$3.06B-4%+2%-7%5.9×43.7%
Illumina ILMN$31.8B+48%+6%21%7.2×27.2%
Thermo Fisher Scientific TMO$257B+53%+8%19%6.2×21.3%
Pacific Biosciences of California PACB$573M+54%+4%-98%6.7×n/a

How MGI Tech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MGI Tech against its 20 peers (data as of 18 Nov 2026)
Measure688114.SSPeer medianRank in peer set
1-month return-20.4%-4.1%2nd lowest of 21
6-month return-3.5%+6.8%9th lowest of 21
Distance from 52-week high-39.0%-29.8%7th lowest of 21
Revenue growth (TTM)+1.6%+7.2%5th lowest of 20
Operating margin-7.4%10.2%2nd lowest of 19
EV / Sales5.9×4.1×4th most expensive of 20
Growth the price implies (Req g, 7 yrs)43.7%12.5%5th most demanding of 16
Growth delivered (Del g)-0.1%+8.9%3rd lowest of 16
Hurdle (Req g minus delivered)+43.8 pp+1.6 ppmost demanding of 16
ROIC minus cost of capital-5.9 pp-0.7 pp4th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
MGI Tech 688114.SSChina$3.06B-4%+2%-7%5.9×43.7%-0.1%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%1.6×12.5%+10.8%
iRhythm IRTCUnited States$3.19B-19%+22%5%3.9×46.9%+23.0%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%4.1×8.7%-4.2%
Zhende Medical 603301.SSChina$3.26B-10%+8%7%4.8×22.9%-16.1%
iRay Technology 688301.SSChina$3.31B-30%+58%24%6.9×n/an/a
AtriCure ATRCUnited States$2.82B+91%+14%3%4.6×54.2%+20.9%
TransMedics TMDXUnited States$3.35B+42%+28%12%5.1×38.4%+88.2%
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%5.0×-0.4%+7.2%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%5.0×n/an/a
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%2,133.8×n/an/a
Axogen AXGNUnited States$3.40B+33%+24%-5%11.5×52.6%+14.9%
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%3.7×10.0%+10.0%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%1.2×8.6%+8.9%
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%2.0×-1.2%+8.0%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%3.5×45.4%+3.8%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a4.8×-1.2%+8.1%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%3.3×12.7%+11.0%
EBOS EBO.AXAustralia$2.50B+7%+3%3%0.4×4.7%+6.8%
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%3.6×n/an/a

Questions

Who are MGI Tech's main competitors?
Named competitors: Illumina (ILMN), Thermo Fisher Scientific (TMO), Pacific Biosciences (PACB). The cockpit's measured peer set (industry) also includes Carl Zeiss Meditec (AFX.DE), iRhythm (IRTC), Lepu Medical Technology (Beijing) (300003.SZ), Zhende Medical (603301.SS), iRay Technology (688301.SS), AtriCure (ATRC).
Is MGI Tech expensive compared with its peers?
On ev / sales it trades at 5.9× against a peer median of 4.1×, 4th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +44 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has MGI Tech stock performed?
Over six months to 18 Nov 2026 the shares returned -3.5% against +6.8% for the median peer; over one year -26.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.